Form 4 for ATRA Atara Biotherapeutics, Inc.
Accepted 2026-09-04 18:20:04 ET · period of report 2026-09-04 · accession 0000905148-26-004085 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-09-04 18:20 | 2026-09-04 | ATRA | Cherry Brian N | Dir | P - Purchase | $9.60 | +104.2K | 166.5K | +167% | +$1000.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-09-04 | P | A | 104,166 | $9.60 | 166,486 | D | — | — | (F1) Represents shares purchased by the Reporting Person from the Issuer, through its sales agent, pursuant to that certain Sales Agreement, dated November 1, 2023, by and between the Issuer and TD Securities (USA) LLC. |